• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Canada Pharmaceuticals and Healthcare Report Q4 2008 - Product Image

Canada Pharmaceuticals and Healthcare Report Q4 2008

  • ID: 680189
  • December 2008
  • Region: Canada
  • 74 Pages
  • Business Monitor International

FEATURED COMPANIES

  • Apotex
  • GlaxoSmithKline
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi-Aventis
  • MORE

The Canadian drug market should record reasonable growth in local currency terms over the forecast period, reaching a value of US$29.3bn in 2012. Fluctuations in the exchange rate, however, will mean that there will be greater variations in the pharmaceutical market in US dollar terms. Overall, growth will be slower than over the previous five years, owing to government cost-containment measures, aimed at curbing Canada’s high consumption. Patent expiries should have the dual impact of suppressing growth in the patented-drug sector while driving the generics sector forward. Indeed, by 2012, we expect generic-drug expenditure to reach US$5.5bn.

The Canadian government is reportedly set to invest CAD1mn (US$0.99mn) to establish a network of pharmaceutical research centres that will assess the safety and effectiveness of drugs after they have been launched. The network will be a part of the Food and Consumer Safety Action Plan, which was launched by Canada in December 2007. We believe that research-based drugmakers are unlikely to welcome another layer of regulations in an already difficult operating environment

Meanwhile, the first approval of Swiss firm Basilea Pharmaceutica's READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Apotex
  • GlaxoSmithKline
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi-Aventis
  • MORE

Executive Summary 5
Canada Pharmaceuticals And Healthcare Industry SWOT 6
Canada Political SWOT 7
Canada Economic SWOT 7
Pharmaceutical Business Environment Ratings 8
Table: Americas Pharmaceutical Business Environment Rating 8
Limits Of Potential Returns 8
Risks To Realisation Of Returns 9
Canada – Market Summary 10
Regulatory Regime11
Pricing And Reimbursement Issues 14
Ontario Invests In Drug Industry 16
Industry Developments19
Product Approvals And Launches 24
Pharmaceutical Re-import Policy 26
Company Activity 27
National Pharmaceuticals Strategy 33
Generics Sector 34
Research And Development Sector 35
Pharmacy Sector 37
Industry Forecast Scenario 39
Overall Market Forecast 39
Table: Canadian Drug Market Indicators, 2005-2012 40
Key Growth Factors – Industry 40
Table: Canadian Health Expenditure Indicators, 2005-2012 41
Key Growth Factors – Macroeconomic 42
Table: Canada – Economic Activity 43
OTC Market Forecast 44
Table: Canadian OTC Drugs Market Indicators, 2006-2012 (US$mn unless otherwise stated) 45
Generics Market Forecast 46
Table: Canadian Generics Market Indicators, 2005-2012 47
Patented Market Forecast 48
Table: Canadian Patented Market Indicators, 2005-2012 48
Medical Device Market 49
Table: Canada’s Medical Device Market Forecast, 2004-2012 (US$mn unless otherwise stated) 50
Export/Import Forecasts 51
Table: Sectoral Trade Indicators, 2004-2012 (US$mn) 52
Other Healthcare Data Forecasts 52
Table: Canadian Socio-Demographic Indicators 52
Competitive Landscape53
Table: Canada’s Leading Generics Firms, 2006 53
Company Profiles54
Leading Multinational Manufacturers 54
Pfizer 54
Merck & Co 56
GlaxoSmithKline 58
Sanofi-Aventis 60
Novartis 62
Indigenous Manufacturers 63
Apotex 63
Country Snapshot: Canada Demographic Data66
Section 1: Population 66
Table: Demographic Indicators, 2005-2030 66
Table: Rural/Urban Breakdown, 2005-2030 67
Section 2: Education And Healthcare 67
Table: Education, 2000-2003 67
Table: Vital Statistics, 2005-2030 67
Section 3: Labour Market And Spending Power 68
Table: Employment Indicators, 2001-2006 68
Table: Consumer Expenditure, 2000-2012 (US$) 69
Table: Average Annual Manufactuing Wages, 2000-2012 69
BMI Forecast Modelling70
How We Generate Our Pharmaceutical Industry Forecasts 70
Pharmaceutical Business Environment Ratings Methodology 70
Ratings Overview 71
Table: Pharmaceutical Business Environment Indicators 72
Weighting 73
Table: Weighting Of Components 73
Sources 73

Note: Product cover images may vary from those shown

-Pfizer
-Merck & Co
-GlaxoSmithKline
-Sanofi-Aventis
-Novartis
-Apotex

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos